grant
Informing optimal dosing of the future antimalarial, artemether-lumefantrine plus amodiaquine, in key neglected target populations of children with severe acute malnutrition and adults living with HIV
Organization KAMUZU UNIVERSITY OF HEALTH SCIENCESLocation BLANTYRE, MALAWIPosted 1 Sept 2024Deadline 31 Aug 2029
NIHUS FederalResearch GrantFY20250-11 years old21+ years oldAIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAcuteAdultAdult HumanAfricaAfricanAmodiaquinAmodiaquineAnti-Retroviral AgentsAnti-malarial drug resistanceAnti-malarial drug resistantAnti-malarialsAreaArtemisininsAwardBioavailabilityBiological AvailabilityBlood PlasmaChildChild YouthChildren (0-21)ClinicalClinical PharmacologyClinical Trials DesignCombined Modality TherapyComplexDataDerivationDerivation procedureDevelopmentDoseDrug CombinationsDrug KineticsDrugsExclusionFatsFatty acid glycerol estersFutureHIVHourHuman Immunodeficiency VirusesIndividualLAV-HTLV-IIILeadershipLicensingLymphadenopathy-Associated VirusMalariaMalaria preventionMalawiMalnutritionMedicationMultimodal TherapyMultimodal TreatmentNutritional DeficiencyNyasalandO-methyldihydroartemisininePaludismParasite resistanceParasitesPersonsPharmaceutical PreparationsPharmacokineticsPharmacologyPhase 3 Clinical TrialsPhase III Clinical TrialsPhase III studyPhysiologic AvailabilityPlasmaPlasma SerumPlasmodium InfectionsPopulationProduct LabelingRecurrenceRecurrentRegimenResearchResistanceReticuloendothelial System, Serum, PlasmaRiskSafetySubgroupSupplementationTarget PopulationsTherapeuticTimeUndernutritionVirus-HIVWorkWorld Health Organizationabsorptionadulthoodadverse consequenceadverse outcomeanti-malarial agentsanti-malarial drugsanti-malarial resistanceanti-retroviralantiretroviral therapyantiretroviral treatmentarteannuinartemetherartemisininebenflumetolcareercareer developmentclinical translationclinically translatablecombination therapycombined modality treatmentcombined treatmentdevelopmentaldietary deficiencydrug/agentearly clinical trialearly phase clinical trialefficacy clinical trialfallshigh riskinnovateinnovationinnovativekidslumefantrinemalnourishedmedical specialistmulti-modal therapymulti-modal treatmentneglectnovelnutrition deficiencynutrition deficiency disordernutritional deficiency disorderparasite resistantpharmacodynamic modelphase 3 studyphase III protocolprevent malariaqinghaosuquing hau sauquinghaosuresistance in parasiteresistance mechanismresistance to Parasiteresistance to anti-malarial drugresistantresistant mechanismresistant parasiteresistant to Parasiteresistant to anti-malarial drugskillstoolyoungster
Description preview
PROJECT SUMMARY/ABSTRACT
This award will allow Dr Clifford George Banda to characterise the pharmacokinetic and
safety profiles of two long-acting artemisinin partner drugs, lumefantrine and amodiaquine
and their active metabolites when administered as artemether-lumefantrine plus
amodiaquine (ALAQ) in African young children with uncomplicated…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click